With an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis.
The oversubscribed Series A of $165 million (~€143 million) was co-led by two strong VCs in the European biotech space, Sofinnova Partners (which, less than a year ago, also co-founded the company) and Jeito Capital. Other participants in the funding are Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.